Anavex Life Sciences opened lower at $1.05, compared with its previous close of $1.06. In the last trading session, the stock traded between $0.98 and $1.06. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Anavex Life Sciences is now worth
$ 4.39
Resulting in a loss of
$ 95.61 (95.61%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
$-0.07 (-6.98%)
Day High
$1.06
Day Low
$0.98
Day Open
$1.05
Prev Close
$1.06
Volume
11,21,739
1W Return
-21.43%
1M Return
-34.92%
3M Return
-71.84%
6M Return
-69.57%
1Y Return
-85.61%
Market Cap ($ Mn)
91
PE Ratio
-
PB Ratio
2.46
PEG Ratio
-
ROE
-44.87%
ROCE
-49.40%
EPS (TTM)
$0.08
1 Week
-21.43%
1 Month
-34.92%
3 Months
-71.84%
6 Months
-69.57%
9 Months
-74.59%
Anavex investors face Nov 30 deadline in securities class action
Lead plaintiff deadline for Anavex Life Sciences class action is November 30, 2026. Class period covers purchases between November 26, 2025, and August 28, 2026. Allegations center on inadequate internal controls and understated regulatory risks. Stock declined 5.55% and 6.35% following two separate corrective disclosures.
TodayRosen Law leads Anavex class action; lead plaintiff deadline Nov 30
Rosen Law Firm, first filer, reminds Anavex investors of Nov 30, 2026 lead plaintiff deadline. Class action alleges misleading disclosures on internal controls and regulatory risks. Stock fell 34.61% following EMA application withdrawal in March 2026. Former CEO Christopher Missling terminated for misconduct linked to control failures.
22 days agoAnavex completes blarcamesine DDI and ADME studies; FDA clears FXS IND
Anavex completed clinical conduct of DDI and ADME studies for blarcamesine. Preliminary results show no serious adverse events in both studies. FDA cleared IND for Phase 2a trial in Fragile X syndrome with ~60 participants. November FDA meeting planned to discuss pediatric inclusion in Rett syndrome Phase 3.
23 days agoAnavex stockholders elect all six incumbent directors at annual meeting
Anavex Life Sciences stockholders elected all six incumbent director nominees at the 2026 Annual Meeting. The result rejects activist PVG Asset Management's campaign despite Glass Lewis recommending votes against two incumbents. ISS had supported the current board, citing active oversight and recent leadership changes. Preliminary results will be finalized in an 8-K filing; committee assignments to be updated post-certification.
1mo agoRosen Law Firm probes Anavex Life Sciences over CEO ouster
Rosen Law Firm investigates Anavex Life Sciences (NASDAQ: AVXL) for potential securities fraud. Probe triggered after CEO Christopher Missling was terminated for cause in May 2026. Shareholders may join class action to recover losses without upfront fees. Firm cites history of recovering billions in securities settlements globally.
1mo agoPVG Asset Management unveils 100-day turnaround plan for Anavex
PVG Asset Management holds 337,663 shares of Anavex Life Sciences (NASDAQ: AVXL). Plan includes hiring a CNS-focused CEO and rebuilding the clinical team. Phase 3 Alzheimer's trial design to be de-risked via a special board committee. Pursuit of non-dilutive financing and pharma partnerships for Parkinson's and schizophrenia. All board members and management required to hold meaningful stock ownership.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Anavex Life Sciences is now worth
$ 4.39
Resulting in a loss of
$ 95.61 (95.61%)
Note: Past profits do not guarantee future returns.
